Your institution may have access to this item. Find your institution then sign in to continue.
Title
Xtandi Now Indicated for the Treatment of Metastatic Castration-Sensitive Prostate Cancer.
Abstract
The article discusses approval of a new indication for enzalutamide marketed as Xtandi by Pfizer and Astellas by food and drug administration for the treatment of patients with metastatic castration-sensitive prostate cancer. It mentions that the approval of enzalutamide was based on results of the ARCHES study, a double-blind, randomized, multinational, phase 3 clinical trial of patients with metastatic castration-sensitive prostate cancer.